Endocrinology (all articles)
RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.
28 Jun, 2021 | 09:46h | UTC
RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.
28 Jun, 2021 | 09:45h | UTCTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D – MedPage Today (free registration required)
Guideline | Perimenopause and Postmenopause – Diagnosis and Interventions.
28 Jun, 2021 | 09:32h | UTC
Perspective | Why are people with obesity more vulnerable to COVID?
25 Jun, 2021 | 10:21h | UTCWhy Are People with Obesity More Vulnerable to COVID? – Scientific American
Viewpoint | Progress in Pharmacotherapy for Obesity.
24 Jun, 2021 | 09:46h | UTCProgress in Pharmacotherapy for Obesity – JAMA (free for a limited period)
See also: Semaglutide’s Success Could Usher in a “New Dawn” for Obesity Treatment – JAMA (free for a limited period)
Audio clinical review: Semaglutide for Weight Loss
Cohort study: no association was found between statin therapy and cognitive decline or incident dementia in older adults.
23 Jun, 2021 | 10:14h | UTCCommentaries: Statin Therapy Not Associated With Cognitive Decline, Dementia in Older Adults, Study Says – American College of Cardiology AND Effect of Statins on Cognitive Decline and Dementia in Older Adults – American College of Cardiology
Expert analysis | The global prevention of cardiovascular disease among people living with diabetes: leading with heart.
23 Jun, 2021 | 10:13h | UTCOriginal publication and resources: The Global Diabetes Compact – World Health Organization
See also: The WHO Global Diabetes Compact: a new initiative to support people living with diabetes – The Lancet Diabetes & Endocrinology (free registration required)
Study shows overuse of levothyroxine in patients with subclinical hypothyroidism despite evidence of no benefit.
22 Jun, 2021 | 09:57h | UTCLevothyroxine Use in the United States, 2008-2018 (free for a limited period)
Editorial: Overuse of Levothyroxine in Patients With Subclinical Hypothyroidism: Time to “Leve”-Out-Thyroxine – JAMA Internal Medicine (free for a limited period)
Related: RCT: Levothyroxine does not reduce the risk of developing depressive symptoms in older adults with subclinical hypothyroidism (studies and guidelines on the subject)
Expert analysis: the ever-growing role of coronary artery calcium in primary prevention.
22 Jun, 2021 | 09:54h | UTC
Commentary on Twitter
New ACC Expert Analysis: The Ever-Growing Role of Coronary Artery Calcium in Primary Prevention.
More: https://t.co/GSsEqkoMbi @miguelcainzos23 @rblument1 @AndyGagel #ASCVD #cvPrev pic.twitter.com/7cUOAIArz9
— American College of Cardiology (@ACCinTouch) June 22, 2021
Systematic review: Safety and effectiveness of metformin in patients with reduced renal function – safe and beneficial at a eGFR of 45 mL/min/1.73m2 or higher; possibly harmful at an eGFR of less than 30 mL/min/1.73m2.
17 Jun, 2021 | 09:37h | UTC
Commentary on Twitter
Safety of metformin for T2 diabetes in people with reduced kidney function
Associated with ⬇️ mortality and no ⬆️ risk of acidosis at an eGFR of > 45
Associated with fewer benefits & possible ⬆️ in the risk of acidosis at an eGFR <30 https://t.co/uOyarn11hM@goKDIGO pic.twitter.com/Ca05gc7FHi
— Prof Kamlesh Khunti (@kamleshkhunti) June 16, 2021
More data suggests no cardiovascular benefit from Omega-3 supplementation – secondary analysis of STRENGHT trial did not show an association between achieved Omega-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk.
8 Jun, 2021 | 09:19h | UTCOriginal study: #AHA20 – Randomized trial: High-dose Omega-3 fatty acids did not reduce the risk of cardiac events in patients at high cardiovascular risk
Perspective | Could statins do more than lower cholesterol in patients with COVID-19? – “Don’t Start, Don’t Stop”.
6 Jun, 2021 | 23:49h | UTCCould Statins Do More Than Lower Cholesterol in Patients With COVID-19? – JAMA
M-A: Direct comparison of preoperative imaging modalities for localization of primary hyperparathyroidism – “choline PET-CT would be the best preoperative imaging modality for localization of primary hyperparathyroidism”.
6 Jun, 2021 | 23:40h | UTCJAMA Otolaryngology – Head & Neck Surgery (free for a limited period)
Invited commentary: Localization Studies for Parathyroid Surgery (free for a limited period)
RCT: Among patients with Type 2 diabetes treated with basal insulin with poor glycemic control (mean baseline HbA1c level = 9.1%), continuous glucose monitoring reduced HbA1c level by 0.4% compared to usual care (8.0% and 8.4%). Patient engagement (i.e., adherence, diet, physical activity in response to CGM readings) was the most likely source of improved glycemic control.
3 Jun, 2021 | 10:54h | UTCEditorial: Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes – JAMA
Commentary: Studies support wider CGM access in type 2 diabetes – medwire News
Commentary on Twitter
Continuous glucose monitoring resulted in better glycemic control compared with blood glucose meter monitoring in adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin https://t.co/D0y7B8JsJE
— JAMA (@JAMA_current) June 2, 2021
Podcast | Osteoporosis in Primary Care.
1 Jun, 2021 | 08:06h | UTC#277 Bone Up on Osteoporosis in Primary Care with Dr. Carolyn Crandall – The Curbsiders
Study shows acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection.
26 May, 2021 | 08:37h | UTCRelated: Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes? – The Lancet Diabetes & Endocrinology AND SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment – Cell Metabolism
Commentary on Twitter
For at least 2 months after COVID-19 in people without #diabetes, glucose regulation can be abnormal, along with insulin resistance and abnormal cytokineshttps://t.co/P1xa0lx2c4 @NatMetabolism @PAOLOFIORINA @FiorinaLab pic.twitter.com/Lu7GDMjzdy
— Eric Topol (@EricTopol) May 25, 2021
Podcast | Bariatric Surgery for the Internist – Patient selection, perioperative management, and post-operative care.
25 May, 2021 | 08:37h | UTC#275 Bariatric Surgery for the Internist with Dr. Vivian Sanchez – The Curbsiders
The state of diabetes treatment coverage in 55 low-income and middle-income countries – fewer than one in ten people with diabetes in LMICs receive comprehensive care such as low-cost medicines to reduce blood sugar, blood pressure and cholesterol levels, in addition to counseling on diet, exercise and weight.
24 May, 2021 | 08:18h | UTCCommentary: Vast under-treatment of diabetes seen in global study – Michigan Medicine
24-week randomized controlled trial: Mixed tree nut snacks resulted in similar weight loss and increased satiety compared to refined carbohydrate snacks in a weight loss and maintenance program.
20 May, 2021 | 08:28h | UTCCommentary: Mixed tree nut snacks result in significant weight loss and improved satiety – News Medical
SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment.
19 May, 2021 | 08:49h | UTCSARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment – Cell Metabolism
Commentary on Twitter
A new report reinforces the capability for #SARSCoV2 to infect and kill pancreatic β-islet cells, affect insulin secretion https://t.co/4tpIVNpjTf @Cell_Metabolism #diabetes @StanfordMed @stanfordimmuno @UCSF and collaborators pic.twitter.com/dG027CXS5e
— Eric Topol (@EricTopol) May 18, 2021
#ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19.
17 May, 2021 | 08:49h | UTC
Commentaries on Twitter
DARE-19 trial #ACC21 @ACCinTouch
Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile
🎯 Do not discontinue SGLT2i in 🏥 for #COVID19
Full slideset available in 👇https://t.co/RPi5mpPbbN pic.twitter.com/B9VQdSSAFu
— Enrique Santas (@SantasEnrique) May 16, 2021
DARE-19 findings presented at #ACC21 show #dapagliflozin didn’t significantly ⬇️ risk of organ failure or death or improve recovery in patients hospitalized w/ #COVID19. However, data suggest the SGLT2 inhibitor was well tolerated in acutely ill patients. https://t.co/YjYxbuc952 pic.twitter.com/J4PqwvGpLJ
— American College of Cardiology (@ACCinTouch) May 16, 2021
Perspective | Start-ups tout continuous glucose monitoring for people without diabetes – “aside from anecdotal success stories, there’s little evidence that people with normal glucose responses benefit from tracking their blood glucose”.
14 May, 2021 | 08:20h | UTCStart-ups Tout Continuous Glucose Monitoring for People Without Diabetes – JAMA
Study shows BMI cut-offs for obesity and diabetes risk do not work for non-white populations.
12 May, 2021 | 08:41h | UTC
Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.
12 May, 2021 | 08:42h | UTCEditorial: Newer drug treatments for type 2 diabetes
Commentary on Twitter
New guideline provides risk-stratified recommendations about when to add SGLT-2 inhibitors or GLP-1 receptor agonists to existing treatment for adults with type 2 diabetes.#BMJInfographic provides an overview of the recommendations @will_s_t https://t.co/G7267xadmH pic.twitter.com/vKGj5xlm4Y
— The BMJ (@bmj_latest) May 11, 2021
M-A: Metabolic–bariatric surgery is associated with increased long-term survival in adults with obesity, the effects being more pronounced for people with pre-existing diabetes
11 May, 2021 | 09:11h | UTCAssociation of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants – The Lancet (link to abstract – $ for full-text)